• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Risk Of Stroke Effectively Reduced By Simple 2-Drug Combination
Results of a Phase III clinical trial showed that a simple drug regimen of two anti-clotting drugs - clopidogrel and aspirin- lowered the risk of stroke by almost one-third, compared to the standard therapy of aspirin alone, when given to patients who had minor or transient stroke symptoms to prevent subsequent attacks. Described this week in the New England Journal of Medicine (July 4, 2013 print issue), the clinical trial was conducted at multiple sites in China and designed in partnership with a physician at UC San Francisco...
Source: Health News from Medical News Today - June 28, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Drug Combo Cuts Stroke Risk After TIA
A simple combination of two anti-clotting drugs, clopidogrel and aspirin, can cut the risk of a stroke in patients who have already experienced a mini-stroke or transient ischemic attack (TIA). This was the result of a phase 3 clinical trial conducted in China with the help of a US physician who says it could change the standard of care in the US. The investigators report their findings in the 26 June online issue of the New England Journal of Medicine, NEJM. The trial took place at several sites in China and was designed in partnership with S...
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Novel Oral Anticoagulants and Gastrointestinal Bleeding: a Case for Cardiogastroenterology
With the rapidly evolving cardiology drug pipeline for treatment of acute coronary syndrome (ACS), gastroenterologists have witnessed the emergence of a new population of patients who are vulnerable to gastrointestinal (GI) bleeding: the chronic cardiac patient. ACS, causing myocardial infarction (MI) and unstable angina, and atrial fibrillation are the signature conditions of the chronic cardiac patient. The morbidity and mortality of ACS is significant. Chronic cardiac patients are prescribed complex antithrombotic therapy (CAT) (ie, aspirin [ASA] plus a thienopyridine, eg, clopidogrel [Plavix; Bristol-Myers Squibb/Sanof...
Source: Clinical Gastroenterology and Hepatology - January 23, 2013 Category: Gastroenterology Authors: Neena S. Abraham Tags: Comment From the Editor Source Type: research